Roie Tzadok

Dr. Roie Tzadok

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2020 in Pain Research and Management
Verified
Journal Article
Open access
PDF file
RTRoie Tzadok
Roie Tzadok
Jacob AblinJacob Ablin
Jacob Ablin
Introduction. Fibromyalgia syndrome (FMS) is a pain disorder with an estimated prevalence of 1–5%. It is associated with a variety of somatic and psychological disorders. Its exact pathogenesis is still unclear but is involved with neural oversensitization and decreased conditioned pain modulation (CPM), combined with cognitive dysfunction, memory impairment, and altered information processing. Connectivity between brain areas involved in pain processing, alertness, and cognition is increased in the syndrome, making its pharmacologic therapy complex. Only three drugs, pregabalin, duloxetine, and milnacipran are currently FDA-approved for FM treatment, but many other agents have been tested over the years, with varying efficacy. Areas Covered. The purpose of this review is to summarize current clinical experience with different pharmacologic treatments used for fibromyalgia and introduce future perspectives in developing therapies. Expert Opinion. Future insights into the fields of cannabinoid and opioid research, as well as an integrative approach towards the incorporation of genetics and functional imaging combined with additional fields of research relevant towards the study of complex CNS disorders, are likely to lead to new developments of novel tailor-made treatments for FMS patients.

27 September 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
IBIrit Avni Biron
Irit Avni Biron
TMTali Mishael
Tali Mishael
Eran ZittanEran Zittan
Eran Zittan
MLMoran Livne‐Margolin
Moran Livne‐Margolin
AZAdar Zinger
Adar Zinger
ASAriella Bar-Gil Shitrit
Ariella Bar-Gil Shitrit

23 March 2022 in Case Reports in Gastrointestinal Medicine
Verified
Journal Article
Open access
PDF file
RTRoie Tzadok
Roie Tzadok
SLSharon Levy
Sharon Levy
JAJessie Aouizerate
Jessie Aouizerate
OSOren Shibolet
Oren Shibolet
Immune checkpoint inhibitors have become major therapeutic agents in oncology over the last few years. However, they are associated with a variety of potentially severe autoimmune phenomena. We present a patient with advanced adenocarcinoma of the lung, who presented with acute liver injury two weeks following his first treatment with atezolizumab, rapidly deteriorating to fulminant liver failure. A thorough evaluation of infectious, vascular, metabolic, and autoimmune etiologies did not yield any results. Liver pathology was nonspecific. Using RUCAM as a causality assessment method indicated probable connection between atezolizumab and liver damage. To our knowledge, this is the first documented report of a patient developing acute liver failure shortly after immune checkpoint inhibitor initiation.

28 August 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
VRVered Rosenberg
Vered Rosenberg
RTRoie Tzadok
Roie Tzadok
Gabriel ChodickGabriel Chodick
Gabriel Chodick
RKRevital Kariv
Revital Kariv

1 December 2017 in Journal of Surgical Research
Verified
Journal Article
Closed access
AHAyal Hassidim
Ayal Hassidim
SMSharon Bratman Morag
Sharon Bratman Morag
MGMoshe Giladi
Moshe Giladi
YDYael Dagan
Yael Dagan
RTRoie Tzadok
Roie Tzadok
ADAmir Dagan
Amir Dagan

8 September 2022 in American Journal of Nephrology
Verified
Journal Article
Open access
PDF file
AGAyelet Grupper
Ayelet Grupper
ARAviad Rabinowich
Aviad Rabinowich
ISIdan Ben Shabat
Idan Ben Shabat
RTRoie Tzadok
Roie Tzadok
DSDoron Schwartz
Doron Schwartz
HKHelena Katchman
Helena Katchman
Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality after kidney transplantation. Metabolic syndrome is common in renal transplant recipients and is associated with increased CVD risk in those patients. Nonalcoholic fatty liver disease (NAFLD) is considered to be the hepatic manifestation of a multi-system disorder, including CVD and metabolic syndrome. The data about prevalence of NAFLD before kidney transplantation and its consequences following transplantation are scarce. Methods: A retrospective study of metabolic parameters and sonographic evidence of NAFLD, and an analysis of its metabolic outcomes, was performed in 341 consecutive kidney transplant recipients. Results: One-hundred twenty-four (36.4%) kidney recipients had NAFLD before transplantation. The risk of NAFLD before kidney transplantation was independently and significantly related to diabetes (OR = 1.8), male gender (OR = 1.4), older age (every year of age increased the risk by 4%), higher BMI (every increase of 1 kg/m2 increased the risk by 15%), and higher triglycerides level. Mean levels of liver enzymes were similar in patients with and without NAFLD. Recipients with NAFLD before transplantation had a higher prevalence of new onset diabetes, even after adjustment to covariables. In addition, they had a higher increase in liver enzymes, triglycerides, and FIB-4 score, as an indication of liver fibrosis, after transplantation. Furthermore, NAFLD pre-transplantation was independently associated with cardiovascular mortality (HR = 4.4) following kidney transplantation. Conclusions: Sonographic evidence of NAFLD before kidney transplantation is associated with significant metabolic outcomes including de novo diabetes and cardiovascular mortality following transplantation and should be included as part of the assessment of kidney transplant candidate.